OXC 201
Alternative Names: OGG1 inhibitor – Oxcia; OXC-201; TH5487Latest Information Update: 28 Apr 2026
At a glance
- Originator Oxcia
- Class Anti-inflammatories; Antiallergics; Antifibrotics; Antivirals; Small molecules
- Mechanism of Action Oxoguanine glycosylase 1 inhibitors
-
Orphan Drug Status
Yes - Idiopathic pulmonary fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Allergic asthma; Idiopathic pulmonary fibrosis; Viral infections
Most Recent Events
- 21 Apr 2026 Oxcia plans to initiate first in human phase I trial in the beginning of 2027 (PO)
- 14 Oct 2025 OXC 201 receives Orphan Drug status for Idiopathic pulmonary fibrosis, prior to October 2025 (Oxcia pipeline, October 2025)
- 09 Sep 2025 Preclinical trials in Viral infections in Sweden (PO) prior to September 2025